AGIO

Congress Trades

Actor	Trade Size	Last Transaction	Amount Range	Price	Current Price
Gilbert CisnerosDemocrat $8.0k280.9 shares BuyMar 3, 2026 $1k-$15k $28.48 $28.62

News

zacks.comAGIO Secures Global Rights to Late-Stage Rare Blood Disorder Candidatezacks.comJun 2

seekingalpha.comAgios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare Hematology Transcriptseekingalpha.comJun 1

proactiveinvestors.comAgios Pharmaceuticals licenses global rights to Oscotec's SYK inhibitor cevidoplenibproactiveinvestors.comJun 1

zacks.comAGIO Halts Tebapivat Development in Myelodysplastic Syndromeszacks.comJun 1

globenewswire.comAgios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenibglobenewswire.comJun 1

Trade AGIO

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

CEO: Brian Goff
IPO Date: Jul 24, 2013

Market Data

Open: $28.95
High: $29.39
Low: $28.13
Volume: 561.2K
52W High: $46.00
52W Low: $22.24

Valuation

Market Cap: $1.7B
Enterprise Value: $1.6B

Financials

Free Cash Flow: $-377M
Revenue: $54M
Net Income: $-413M
Cash: $89M
Debt: $62M

Events

EarningsJul 30

EPS est. -1.64975